Your browser is no longer supported. Please, upgrade your browser.
Settings
BIIB Biogen Inc. daily Stock Chart
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E16.27 EPS (ttm)17.69 Insider Own0.10% Shs Outstand218.90M Perf Week-3.17%
Market Cap62.99B Forward P/E13.81 EPS next Y20.84 Insider Trans-11.49% Shs Float216.61M Perf Month-10.03%
Income3.89B PEG1.83 EPS next Q4.99 Inst Own88.30% Short Float1.21% Perf Quarter-4.92%
Sales11.42B P/S5.52 EPS this Y24.00% Inst Trans-0.73% Short Ratio1.64 Perf Half Y17.77%
Book/sh55.36 P/B5.20 EPS next Y3.16% ROA18.50% Target Price338.22 Perf Year-0.73%
Cash/sh19.72 P/C14.60 EPS next 5Y8.91% ROE36.00% 52W Range223.02 - 333.65 Perf YTD-6.06%
Dividend- P/FCF19.35 EPS past 5Y31.30% ROI23.50% 52W High-13.75% Beta0.75
Dividend %- Quick Ratio2.80 Sales past 5Y17.90% Gross Margin87.50% 52W Low29.03% ATR10.44
Employees7350 Current Ratio3.20 Sales Q/Q6.40% Oper. Margin47.60% RSI (14)39.59 Volatility4.45% 2.85%
OptionableYes Debt/Eq0.54 EPS Q/Q13.40% Profit Margin34.00% Rel Volume3.90 Prev Close289.54
ShortableYes LT Debt/Eq0.54 EarningsOct 26 BMO Payout0.00% Avg Volume1.60M Price287.77
Recom2.00 SMA20-6.25% SMA50-4.10% SMA2002.03% Volume6,247,804 Change-0.61%
Dec-09-16Reiterated Stifel Hold $291 → $298
Nov-08-16Initiated Mizuho Buy $290
Nov-07-16Upgrade Piper Jaffray Neutral → Overweight
Nov-07-16Upgrade Leerink Partners Mkt Perform → Outperform
Sep-06-16Downgrade Jefferies Buy → Hold
Jun-29-16Initiated Bernstein Outperform
Jun-07-16Downgrade Citigroup Buy → Neutral
Feb-25-16Initiated Citigroup Buy $345
Jan-20-16Initiated Credit Suisse Neutral
Jan-07-16Initiated Standpoint Research Buy $360
Dec-04-15Resumed Wells Fargo Outperform
Oct-22-15Reiterated H.C. Wainwright Buy $380 → $360
Sep-09-15Initiated Jefferies Buy
Sep-01-15Initiated Raymond James Strong Buy $400
Aug-11-15Initiated H.C. Wainwright Buy $380
Jul-27-15Upgrade Bernstein Mkt Perform → Outperform $436 → $385
Jul-27-15Reiterated RBC Capital Mkts Outperform $525 → $450
Jul-27-15Reiterated Argus Buy $450 → $360
Jul-27-15Downgrade Robert W. Baird Outperform → Neutral $480 → $316
Jul-24-15Downgrade BMO Capital Markets Outperform → Market Perform $511 → $360
Dec-10-16 07:41AM  Is Biogen's Aducanumab a Game-Changing Alzheimer's Drug? at Motley Fool
Dec-09-16 05:29PM  Biogen Underplays Promising Alzheimer's Data On Seizure Worries
05:15PM  Week in Review: Dow Scores Five Straight Days of Record Closes
04:14PM  Biotech ETFs: A Short-Lived Boon From Biogen at Barrons.com
04:04PM  Dow, in Another Record Close, Ends With Weekly Gains for Fifth Consecutive Week
03:29PM  [$$] Biotech Bargain: Biogen On Sale After Good News at Barrons.com
02:55PM  Why the latest Alzheimers data is (mostly) great news for Biogen at bizjournals.com
02:37PM  Postive results in study of Alzheimer's
01:55PM  When Will The Dow Hit 20,000? Apple Retakes Key Level, Broadcom Pops
01:51PM  Biogen Shares Up Following Eli Lilly's Failed Alzheimer's Study at TheStreet
01:24PM  [$$] Biogen buoyed by hopes for Alzheimer's drug at Financial Times
12:55PM  Biogen gains on new Eli Lilly Alzheimers data, as beta-amyloid hypothesis lives to see another day at MarketWatch
12:04PM  Stocks Up Again; Apple Strengthens, Reclaims 50-Day Line
11:50AM  Does New Alzheimer's Data Make Biogen Stock a Buy Now? at Motley Fool
11:39AM  Stocks Hold at Records as Health Care Jumps, Crude Surges
11:30AM  Stocks Up, Biogen Rebounds; Why Apple Is Flexing Strength Again
10:39AM  Attention Shifts to Biogen's Alzheimer's Drug in Wake of Lilly Results
10:19AM  Biogen Alzheimer's Drug Shows Promise in Study at Investopedia
09:54AM  Cramer's Stop Trading: BIIB, AAPL
09:39AM  Eli Lilly Continues Alzheimer's Push After Flop, Biogen Extends Rise
08:55AM  Top Analyst Upgrades and Downgrades: Alliance Data, Autodesk, Biogen, Broadcom, Delta Air Lines, Finisar and More at 24/7 Wall St.
08:00AM  Biogen and AbbVie Receive Health Canada Approval of Once-Monthly ZINBRYTA (Daclizumab Beta) for Multiple Sclerosis PR Newswire
08:00AM  Biogen and AbbVie Receive Health Canada Approval of Once-Monthly ZINBRYTA (Daclizumab Beta) for Multiple Sclerosis CNW Group
07:55AM  Early movers: LVS, MGM, WYNN, RH, AFL, MTN & more at CNBC
05:51AM  Biogen stock gains on leaked Alzheimer's drug data at bizjournals.com
Dec-08-16 07:34PM  The 3 Best Biotech Stocks for 2017 at Motley Fool
06:16PM  Biogen Presents Data from Phase 1b Study of Investigational Alzheimers Disease Treatment Aducanumab at 2016 Clinical Trials on Alzheimers Disease Meeting Business Wire
05:24PM  Biotechs 'Round-Trip' Trump-Inspired Rally; FDA Appointment Key
05:20PM  Further promising data seen with Biogen Alzheimer's drug -study
04:41PM  Further promising data seen with Biogen Alzheimer's drug-study
04:06PM  Biogen shares rise 1.6% on leaked Alzheimer's drug data at MarketWatch
03:47PM  Biogen Shares Spike on Leaked Alzheimer's Drug Data
12:11PM  INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm Accesswire
10:15AM  Can Biogen solve the Alzheimers drug riddle? We could find out within days at bizjournals.com
10:10AM  Investor Alert - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Biogen Inc. (BIIB) & Lead Plaintiff Deadline: December 23, 2016 Accesswire
Dec-07-16 06:27PM  [$$] US biotech shares tumble as Trump warns on soaring drug prices at Financial Times
02:45PM  Trump Vow On Drug Prices Fails To Stop Rally; Apple Retakes Prior Buy Point
12:51PM  IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm Accesswire
11:19AM  3 Top Healthcare Stocks at Motley Fool
10:48AM  BIIB SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Shareholders of a Class Action Involving Biogen Inc. and a Lead Plaintiff Deadline of December 23, 2016 Business Wire
10:36AM  Drug Stocks Tumble After Trump Vows to Pressure Prices at The Wall Street Journal
Dec-06-16 04:34PM  Can Biogen Beat the Broader Markets in 2017? at Motley Fool
Dec-05-16 03:55PM  Pressure Biosciences CEO On Biological Samples: It's All About How You Break Open A Cell
11:57AM  SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm Accesswire
10:09AM  Paul Tudor Jones Betting On Emerging Markets, Pepsi, Facebook, More at Insider Monkey
10:09AM  Shareholder Alert - - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Biogen Inc. (BIIB) & Lead Plaintiff Deadline: December 23, 2016 Accesswire
Dec-04-16 06:05PM  5 Healthcare Stocks Billionaires Love The Most at Insider Monkey
01:24PM  4 Factors That Catapulted Ionis Pharmaceuticals Inc. 68% Higher in November at Motley Fool
Dec-03-16 08:04AM  Why Eli Lilly Shares Lost 8% in November at Motley Fool
07:00AM  Data Reinforcing the Long-Term Safety and Efficacy of Extended Half-Life Hemophilia Therapies ELOCTATE® and ALPROLIX® Highlighted at 58th ASH Meeting Business Wire
Dec-02-16 12:35PM  Biogen Spinoff Gets Gene Therapy Drugs (BIIB, SGMO) at Investopedia
12:10PM  Biogen MS Drug Sued for Patent Infringement (BIIB) at Investopedia
08:03AM  3 Things You Need to Know About Ionis Pharmaceuticals' Pipeline at Motley Fool
06:10AM  Biogen may have edge in high-stakes Tecfidera patent battle, analyst says at bizjournals.com
12:25AM  [$$] Patent Feud Is Underappreciated Risk at Biogen at The Wall Street Journal
Dec-01-16 12:43PM  INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm Accesswire
12:07PM  [$$] Patent Feud Is Underappreciated Risk at Biogen at The Wall Street Journal
10:50AM  ETFs with exposure to Biogen, Inc. : December 1, 2016
10:08AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Biogen Inc. (BIIB) & Lead Plaintiff Deadline December 23, 2016 Accesswire
Nov-30-16 04:22PM  Biogen, Forward Square Off In Multiple Sclerosis Patent Battle
01:51PM  INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm Accesswire
11:02AM  BIIB INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Shareholders of a Class Action Involving Biogen Inc. and a Lead Plaintiff Deadline of December 23, 2016 PR Newswire
09:33AM  Better Buy: Biogen Inc. vs. Amgen at Motley Fool
08:35AM  After Lilly Bombs, Could Alzheimer's Become Healthcare's Trumpshot? at Forbes
08:34AM  Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield
07:38AM  Biogen, Inc. breached its 50 day moving average in a Bearish Manner : BIIB-US : November 30, 2016
Nov-29-16 02:00PM  AbbVies Financial Guidance for 2017
12:04PM  Visualizing Financial Trends With Interactive Charts, Other Topics
11:50AM  Biogen loses $4 billion in market cap on Eli Lilly Alzheimer's news at bizjournals.com
Nov-28-16 03:42PM  IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm Accesswire
02:24PM  [$$] Biogen Unfazed by Lilly Disappointment at Barrons.com
10:07AM  SHAREHOLDER ALERT Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Biogen Inc. (BIIB) & Lead Plaintiff Deadline - December 23, 2016 Accesswire
09:45AM  Biogen in promising but risky limelight after Eli Lillys Alzheimers drug fails at MarketWatch
07:35AM  Short Sellers Grow More Aggressive on Major Biotechs
Nov-25-16 04:58PM  EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Biogen Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm Accesswire
01:14PM  Gurus Invest in Undervalued Biotech Stocks
10:30AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Biogen Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 23, 2016 Business Wire
10:06AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Biogen Inc. (BIIB) & Lead Plaintiff Deadline - December 23, 2016 Accesswire
09:33AM  The Market In 5 Minutes: Black Friday Closes Shortened Trading Week
07:09AM  What Eli Lillys hard fall in Alzheimers treatment race means for its competitors at MarketWatch
07:00AM  Will Lilly's Solanezumab Setback Weigh on Other Alzheimer's Stocks?
12:16AM  [$$] Failure of Another Alzheimers Drug Forces a Reassessment at The Wall Street Journal
Nov-24-16 07:39AM  Is Lilly's Alzheimer's Fail Good for Biogen? (BIIB) at Investopedia
Nov-23-16 07:07PM  Biogen Inc (BIIB) Stock Tumbles In Sympathy To Eli Lilly And Co (LLY), Cmon Man! at Insider Monkey
05:16PM  Drug bust hits healthcare stocks
05:01PM  Eli Lilly's Alzheimer's Drug Is a Bust at Motley Fool
04:29PM  3 Potentially Huge Catalysts for Ionis Pharmaceuticals, Inc. in 2017 at Motley Fool
04:27PM  [$$] Failure of Another Alzheimer's Drug Forces a Reassessment at The Wall Street Journal
04:07PM  Eli Lilly Topples As Alzheimer's Darling Sola Fails; Biogen, Merck Down
03:14PM  3 Biotechs That Don't Pay Dividends -- but Could at Motley Fool
02:49PM  Five Lessons From Today's Pharma Failures at Forbes
01:29PM  Why Biogen Shareholders Lost $3 Billion Today at Motley Fool
01:05PM  Analyst on LLY: In general, I believe Biogen drug is bett...
12:51PM  Trades gone 'fowl': Big losers in large cap S&P
12:26PM  Eli Lilly Alzheimer's Drug Fails Key Trial; Lilly, Biogen Dive
12:21PM  Eli Lilly & Juno Therapeutics plummet after failed drug t...
12:02PM  Biotechs Weigh On Nasdaq; Veeva Up On Earnings; 10-Yr Yield Soars Again
10:29AM  5 Biotech Stocks George Soros Is Buying at Motley Fool
09:45AM  Stocks Open Lower; Deere Soars, Eli Lilly Crumbles
09:15AM  Shares of Eli Lilly Are Down 12% After Trial Miss (LLY, BIIB) at Investopedia
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. It offers TECFIDERA, AVONEX, and PLEGRIDY to treat relapsing forms of multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn's disease; and FAMPYRA to improve walking ability for patients with MS. The company also provides ELOCTATE to treat adults and children with hemophilia A for control of bleeding episodes; ALPROLIX to treat adults and children with hemophilia B for control of bleeding episodes; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat plaque psoriasis. The company's products in Phase III development stage comprise ZINBRYTA, a monoclonal antibody for the treatment of relapsing-remitting MS; Aducanumab for Alzheimer's disease; and ISIS-SMNRx for spinal muscular atrophy. Its Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Amiselimod for multiple autoimmune indications; BAN2401 and E2609 for Alzheimer's disease; Raxatrigine for trigeminal neuralgia; rAAV-XLRS for X-linked juvenile retinoschisis; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise Dapirolizumab pegol for systemic lupus erythematosus (SLE); ISIS DMPK for myotonic dystrophy; Anti-BDCA2 for SLE; Anti-alpha-synuclein for Parkinson's disease; and BIIB063 for sjogren's syndrome. The company has a strategic research collaboration with Ionis Pharmaceuticals, Inc. It offers products primarily through its own sales force, marketing groups, and third parties worldwide. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffDec 01Sale296.534814,2337,360Dec 05 04:34 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffOct 04Sale311.9426281,7287,579Oct 05 04:24 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffOct 03Sale313.00380118,9407,841Oct 04 05:02 PM
Karaboutis AdrianaEVP, Tech, Bus. Sol & Corp AffOct 01Option Exercise0.001,98209,154Oct 04 05:02 PM
DORSA CAROLINEDirectorSep 22Option Exercise53.6427,5701,478,85544,663Sep 26 04:24 PM
DORSA CAROLINEDirectorSep 22Sale314.0027,5708,656,98017,093Sep 26 04:24 PM
SCANGOS GEORGE AChief Executive OfficerJul 21Sale280.0015743,96054,779Jul 22 05:03 PM
Koppel AdamEVP, Strategy and Bus. Dev.Jun 06Sale290.00555160,9502,402Jun 07 04:09 PM
SCANGOS GEORGE AChief Executive OfficerJun 03Sale290.00842244,18054,936Jun 06 08:14 PM
Koppel AdamEVP, Strategy and Bus. Dev.Jun 02Option Exercise0.001,64303,491Jun 06 08:48 PM
SCANGOS GEORGE AChief Executive OfficerJun 01Sale287.97487140,24155,778Jun 02 04:39 PM
SCANGOS GEORGE AChief Executive OfficerMay 31Sale290.003,368976,72056,265Jun 02 04:39 PM
SCANGOS GEORGE AChief Executive OfficerMay 25Sale280.0015743,96059,633May 27 08:59 AM
SCANGOS GEORGE AChief Executive OfficerMay 02Sale274.74487133,79859,790May 04 05:03 PM
Koppel AdamEVP, Strategy and Bus. Dev.Apr 06Sale275.0010228,0501,848Apr 07 05:03 PM
SCANGOS GEORGE AChief Executive OfficerApr 06Sale280.0015743,96060,277Apr 07 05:01 PM
Artavanis-Tsakonas SpyridonEVP, Chief Scientific OfficerApr 02Option Exercise0.0097503,609Apr 05 05:06 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale258.83487126,05060,434Apr 05 05:02 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 25Sale261.9018347,9287,990Feb 26 04:08 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 23Option Exercise0.00636032,140Feb 25 05:05 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 23Option Exercise0.0057908,599Feb 25 04:59 PM
DiPietro KennethEVP Human ResourcesFeb 23Option Exercise0.0063604,237Feb 25 05:01 PM
Koppel AdamEVP, Strategy and Bus. Dev.Feb 23Option Exercise0.0030101,963Feb 25 05:02 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 23Option Exercise0.006602,709Feb 25 05:09 PM
Clancy Paul JExecutive VP and CFOFeb 23Option Exercise0.00579027,143Feb 25 05:13 PM
SCANGOS GEORGE AChief Executive OfficerFeb 23Option Exercise0.002,964062,812Feb 25 04:51 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 17Sale256.16722184,9487,990Feb 19 04:18 PM
SCANGOS GEORGE AChief Executive OfficerFeb 17Sale256.16487124,75059,848Feb 19 04:20 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.003,31604,466Feb 17 06:00 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.003,859027,768Feb 17 05:53 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.001,05702,692Feb 17 05:54 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,274052,364Feb 10 04:19 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 09Sale246.54852210,0527,740Feb 10 04:17 PM
Sandrock AlfredEVP CMO Neuro & NeurodegeneratFeb 08Option Exercise0.001,27809,018Feb 10 04:17 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,026029,666Feb 09 04:51 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,70907,030Feb 09 04:48 PM
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise273.452,466674,3282,466Feb 02 04:05 PM